CTOs on the Move

Endeavor BioMedicines

www.endeavorbiomedicines.com

 
Endeavor is a clinical-stage company developing a best-in-class Hedgehog inhibitor for Idiopathic Pulmonary Fibrosis.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Endeavor BioMedicines raised $62M on 01/07/2021

Similar Companies

Synlogic

Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic`s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the second half of 2022, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic`s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. Synlogic is also working with Roche in a research collaboration focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease and with Ginkgo Bioworks to include additional undisclosed preclinical assets, combining Synlogic`s approach to Synthetic Biotics with Ginkgo`s Codebase and Foundry services.

Waste Reduction

Waste Reduction is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Volcano Corporation

Volcano Corporation designs, develops, manufactures and commercializes a suite of intravascular ultrasound (IVUS) and functional measurement (FM) products that seeks to enhance the diagnosis and treatment of vascular and structural heart disease. The

MindLinc: Duke University BHI

MindLinc: Duke University BHI is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prime Medicine

Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations.